(4-[2-ACETYLAMINO-2-[1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXY-PHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID-DIETHYLESTER
Compound with spectra: 1 NMR
![(4-[2-ACETYLAMINO-2-[1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXY-PHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID-DIETHYLESTER](/api/compound/JxbEfZzpFlH.png?ph=true&h=300&w=458 "(4-[2-ACETYLAMINO-2-[1-(3-CARBAMOYL-4-CYCLOHEXYLMETHOXY-PHENYL)-ETHYLCARBAMOYL]-ETHYL]-BENZYL)-PHOSPHONIC-ACID-DIETHYLESTER")
| SpectraBase Compound ID | JxbEfZzpFlH |
|---|---|
| InChI | InChI=1S/C32H46N3O7P/c1-5-41-43(39,42-6-2)21-26-14-12-24(13-15-26)18-29(35-23(4)36)32(38)34-22(3)27-16-17-30(28(19-27)31(33)37)40-20-25-10-8-7-9-11-25/h12-17,19,22,25,29H,5-11,18,20-21H2,1-4H3,(H2,33,37)(H,34,38)(H,35,36)/t22-,29-/m0/s1 |
| InChIKey | ZWSSVLQCOSZODG-ZTOMLWHTSA-N |
| Mol Weight | 615.7 g/mol |
| Molecular Formula | C32H46N3O7P |
| Exact Mass | 615.307338 g/mol |
| Enantiomer InChIKey | ZWSSVLQCOSZODG-KPURRNSFSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]propanamide
MIYAKAMIDE-B2;N-ACETYL-L-TYROSYL-N-METHYL-L-PHENYLALANYL-(ALPHA-E)-ALPHA,BETA-DIDEHYDROTRYPTAMINE
(TRANS)-ORYZAMIDE-A1
1(2H)-quinoxalinecarboxamide, 3,4-dihydro-3-oxo-N-[(1S)-2-oxo-1-(phenylmethyl)-2-[(phenylmethyl)amino]ethyl]-
N-benzhydryl-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-phenylpropanamide
Labetalol 3TMS
18-([(1-Phenylethyl)amino]carbonyl)-2,13-dioxabicyclo[12.2.2]octadeca-1(16),14,17-triene-15-carboxylic acid
(3S,6R)-3-(1H-indol-3-ylmethyl)-6-phenylpiperazine-2,5-dione
CHBA-(NO2)NLE-PHE-VAL-OME
VALINE-TYROSINE-PROLINE-O-BENZYL TRIPEPTIDE
| Title | Journal or Book | Year |
|---|---|---|
| X-ray Structure of Citrate Bound to Src SH2 Leads to a High-Affinity, Bone-Targeted Src SH2 Inhibitor | Journal of Medicinal Chemistry | 2001 |